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Epstein–Barr virus: Co-opting B-cell memory and migration
Alan B. Rickinson*† and Peter J.L. Lane†
Epstein–Barr virus, a B-lymphotropic human
herpesvirus, persists in vivo by entering the long-lived
memory B-cell compartment. Work with genetically
modified mice suggests that the viral latent membrane
protein LMP1 might allow infected B cells to access the
memory compartment by an unusual route.
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The human γ1-herpesvirus Epstein–Barr virus (EBV) and
its close relatives in Old World primates have evolved a
unique ability to colonise the B-lymphoid system of their
hosts. In the face of host immune responses, these agents
persist as a reservoir of latently infected B cells from
which infectious virus can occasionally be reactivated [1].
This viral strategy depends on an ability to establish at
least three alternative forms of infection in the target B
cells. One is a latent growth-transforming infection in
which the full spectrum of virus latent-cycle proteins is
expressed and the cell is driven into proliferation; the
second is a more restricted form of latency in which the
expression of most, if not all, of these proteins is sup-
pressed and the virus genome is maintained as an episome
in a resting cell; the third is a cytolytic infection in which
the virus itself replicates, with ordered expression of its
many lytic cycle genes, and infectious virus is produced.
The challenge is to understand when and where these dif-
ferent forms of infection are used, and how the transitions
between them are regulated so as to achieve efficient
colonisation of the B-cell system, persistence in the host
and subsequent virus transmission.
Despite the recent generation of an animal model of γ1-
herpesvirus infection [2], our understanding of EBV’s
behaviour in vivo is still limited. Certain insights have
come from studies of patients suffering from infectious
mononucleosis as a result of a primary EBV infection.
During the acute disease, there is local replication of the
orally transmitted virus in the pharynx, but then the infec-
tion appears to spread throughout the lymphoid system
via the clonal expansion of latently infected, growth-trans-
formed B cells. Lymphoblasts expressing markers of trans-
formation by EBV, such as the latent-cycle proteins
EBNA2 and LMP1, can be detected in the tonsillar lym-
phoid tissues of infectious mononucleosis patients [3].
Interestingly, these lymphoblasts are not found, as might
be expected, in the follicles (B-cell areas) of the lymphoid
tissue or their constituent germinal centres, but in the
extrafollicular areas [4]. 
The presumption is that many of the virally transformed B
cells are destroyed by the virus-specific cytotoxic T-cell
response that peaks in the acute phase of the disease. Cer-
tainly virus loads in the B-cell pool fall dramatically as the
asymptomatic virus ‘carrier’ state is established. Studies
on long-term EBV carriers suggest that the small number
of latently infected B cells that remain detectable in the
blood of healthy individuals do not express EBNA2 or
LMP1, have assumed a resting phenotype and are exclu-
sively found within the minority, long-lived memory pop-
ulation [5–7]. How does the virus effect this transition and
secure its place in B-cell memory? Is it dependent upon —
or can it bypass — the normally rigorous process of
antigen-driven memory B-cell selection?
A recent paper from Uchida et al. [8] sheds potentially
interesting new light on this question. The stimulus for
their work was the earlier observation that LMP1, one of
the major effectors of EBV-induced B-cell transformation,
operates at least in part by recruiting and constitutively
activating tumour necrosis factor (TNF) receptor-associ-
ated factors (TRAFs) in the host cell [9]. These are signal-
transducing molecules used by many TNF receptor
family members including CD40, a receptor expressed on
the surface of B cells and involved in the cognate
B-cell–T-cell interactions that underpin most antibody
responses [10]. Indeed many of the proximal effects of
LMP1 signalling and some of the more distal effects
mirror those seen following CD40 ligation [11]. CD40-
deficient mice show specific impairments in memory
B-cell development. So Uchida et al. [8] set out to ask a
seemingly simple question — given the overlap in sig-
nalling pathways downstream of CD40 and LMP1, can
constitutive expression of LMP1 in B cells compensate for
the absence of CD40? 
To appreciate their findings, it is important to have some
idea of the normal sequence of events comprising T-cell-
dependent antibody responses [12]. Initially naïve B cells
that have bound specific antigen move to form cognate
interactions with simultaneously primed, antigen-specific
CD4+ helper T cells at the border between T-cell and
B-cell areas in lymphoid tissues. Following this interaction,
two distinct processes occur (Figure 1a). T-cell help drives
some activated B cells to undergo rapid but limited prolif-
eration to form extrafollicular foci of antibody-producing
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plasmablasts, secreting immunoglobulins of the IgM and/or
IgG isotypes. These cells use their original rearrangements of
germ-line — that is, not somatically mutated — immunoglob-
ulin genes. Virtually all antibodies produced within the first
week of antigenic challenge come from this source. 
Whilst this transient extrafollicular response is on-going,
antigen-specific CD4+ T cells are also recruited into the
follicles where cognate interactions with other antigen-
bearing B cells give rise to germinal centres. These are
regions of clonal B-cell expansion in which somatic muta-
tion of immunoglobulin germ-line variable regions drives
intraclonal diversification of the antigen-binding site of
the immunoglobulin molecule. This then allows the sub-
sequent selection of variants with increased affinity for
antigen, a process termed affinity maturation. Whereas the
extrafollicular plasmablast reaction is dependent on CD4+
T cells only at its initiation, the process of B-cell selection
in the germinal centre involves repeated interactions with
antigen-specific CD4+ T cells. Thereafter, the selected B
cells, many of which have switched from IgM to IgG or
other immunoglobulin isotypes, differentiate either into
long-lived, antibody-producing plasma cells or into
memory B cells (Figure 1a). 
The importance of CD40 signalling to these antibody
responses is clear both in mice lacking CD40 [13] and in
humans lacking CD40 ligand [14]. In both cases, antigenic
challenge results only in an extrafollicular IgM response,
with no antibody isotype switching and no germinal centre
reaction or affinity maturation (Figure 1b). Uchida et al. [8]
asked whether some or all of these defects in CD40-defi-
cient mice could be corrected by constitutively expressing
LMP1 in the B-cell lineage of these mice from a transgene
[15]. As summarised in Figure 1c, they found that LMP1
expression did reconstitute some IgM to IgG class switch-
ing in the initial extrafollicular response, but did not
restore germinal centre formation or the production of
high-affinity antibodies [8].
Underlying this experiment is the premise that impair-
ment of immunoglobulin class switching, germinal centre
formation and affinity maturation in CD40-deficient mice
can be specifically attributed to the absence of CD40 on
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Figure 1
The initial sites of T- and B-cell activation in
the various mouse mutants. (a) Wild-type
mice. Following CD4+ T-cell priming by
CD40-activated dendritic cells (1), T cells
migrate either to B follicles or to the outer T
zone. B cells are activated and migrate to the
outer T zone where they engage the primed T
cells (2). B cells activated here either
differentiate into rapidly proliferating
antibody-secreting plasmablasts that secrete
primary, unmutated antibodies, or migrate to B
follicles to form germinal centres. Primed
CD4+ T cells that migrate into B follicles
foster germinal centre development (3).
Selected somatically mutated B cells colonise
the memory B-cell pool and give rise to
established long-lived plasma cells secreting
high-affinity antibodies. (b) CD40-deficient
mice. T-cell priming is impaired because of
deficient CD40-mediated activation of
dendritic cells. Plasmablasts in the
extrafollicular response fail to undergo
antibody isotype switching to IgG because of
deficient CD40 signalling and germinal
centres fail to form. (c) CD40-deficient mice
expressing LMP1 in the B-cell lineage. Again,
CD4+ T-cell priming is impaired, but
expression of LMP1 in B cells restores some
antibody isotype switching to IgG. Expression
of LMP1 does not restore germinal centre
formation, however. (d) Wild-type mice
expressing LMP1 in the B-cell lineage. Both
T-cell priming and the extrafollicular
plasmablast response are normal in these
mice, but expression of LMP1 paradoxically
prevents germinal centre formation.
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B cells, because these cells can no longer receive signals
from cognate T cells delivered via CD40 ligand on the T-
cell surface. It must be remembered, however, that CD40
is not restricted to the B-cell lineage but is expressed on
certain other cell types, including dendritic cells — the so-
called ‘professional’ antigen-presenting cells that are
important in priming and in orientating the T-cell
response (Figure 1a). In this regard, the CD40–CD40
ligand interaction, in addition to its role in B-cell–T-cell
collaboration, is one of several molecular pairings that
occur sequentially at the interface between dendritic cells
and T cells during T-cell priming. 
In particular, CD40 signalling induces dendritic cells to
upregulate co-stimulatory molecules [16,17], which in
turn induce expression of the chemokine receptor
CXCR5 on the T-cell surface. It is of interest that the
ligand for CXCR5 has recently been identified and
shown to be produced in B-cell follicles [18]. This
chemokine might therefore mediate the specific recruit-
ment of antigen-primed CD4+ T cells from T-cell areas
into the follicles, positioning them correctly for their
essential role in germinal centre formation. Whatever the
effects of LMP1 on B cells, it is likely that failure to con-
summate this interaction between dendritic cells and T
cells in the LMP1-expressing, CD40-deficient animals
would remove one of the essential elements required to
form a classical germinal centre.
As so often happens in science, the most interesting
results from Uchida et al. [8] come from an unexpected
source, in this case from the mice in which B-cell-specific
expression of the LMP1 transgene was occurring in a wild-
type (CD40-positive) background. These mice show small
but detectable increases in B-cell surface levels of the acti-
vation antigen CD23 and the cell adhesion molecule
CD54 compared with non-transgenic littermates. These
cells also show enhanced levels of spontaneous and inter-
leukin-4-induced proliferation and production of IgM and
IgG in vitro. As is clear from work with human B cells [19],
however, LMP1 expression alone is insufficient to confer
a growth-transformed phenotype and the LMP1 trans-
genic mice, at least within the first few months of life,
showed no obvious abnormalities in the size, cell composi-
tion or architecture of secondary lymphoid tissues. 
Following antigenic challenge, these animals mounted
the initial extrafollicular B-cell response, with antigen-
specific IgM and IgG production comparable to that
seen in wild-type animals. Interestingly, however, the
constitutive expression of LMP1 in B cells prevented
germinal centre formation yet, despite this, the antibody
response appeared to be of high affinity (Figure 1d). It
is not yet clear whether this reflects somatic mutation
and affinity maturation occurring in the absence of con-
ventional germinal centres, as has been reported in rare
circumstances, or whether it reflects an extended life of
higher affinity clones from within the germ-line-encoded
extrafollicular response. The point will only be resolved
by sequencing the immunoglobulin variable regions of
the responding cells.
Of most immediate interest is the finding that LMP1
expression abrogates germinal centre formation. This
effect is reminiscent of in vitro studies in which the LMP1
gene was ectopically expressed in EBV-negative Burkitt’s
lymphoma cell lines — that is, in human B cells displaying
a classical germinal centre cell phenotype. One of the viral
protein’s numerous effects in this cell background was to
block expression of Bcl6 [20], a transcription factor that is
selectively expressed in germinal centre B cells and essen-
tial for germinal centre development [21,22]. This sug-
gests that LMP1 actively prevents acquisition of the
germinal centre phenotype. 
At this point, it is worth returning to acute infectious
mononucleosis patients and the observation that EBV-
transformed (LMP1-expressing) B lymphoblasts are
mainly found in an extrafollicular location in tonsillar
tissues rather than in germinal centres or in the remainder
of the follicular B-cell area [4]. The work from Uchida
et al. [8] might well explain the exclusion from germinal
centres, but to understand the general exclusion from fol-
licles we again need to turn to the subject of chemokines
and their control over lymphocyte migration. Just as
primed CD4+ T cells are attracted to B-cell areas by
upregulating the appropriate chemokine receptor CXCR5,
evidence suggests that antigen-stimulated B cells can be
attracted in the opposite direction by upregulating another
chemokine receptor, CCR7, one of whose ligands is pro-
duced by dendritic cells in the T-cell zone of secondary
lymphoid tissues [23]. Interestingly, CCR7 was first
cloned as an EBV-induced (perhaps LMP1-induced?)
gene in human B cells [24]. The virus may therefore
dictate the extrafollicular location of its transformed cells
through CCR7 upregulation.
Once primary infection is over and EBV is embedded in
the memory B-cell pool, it is interesting to reflect on how
the virus might again exploit B-cell migration to its own
ends. Memory B cells either circulate in the bloodstream or
remain resident at specific sites in lymphoid tissue, adja-
cent to the subepithelial sinus in tonsil, for instance [25].
On re-exposure to antigen, these memory cells again
engage T cells in the extrafollicular area and proliferate
extensively, giving rise both to newly formed plasma cells
and to more memory cells. Such plasma cells normally relo-
cate from lymphoid tissue to bone marrow but, in the
tonsil, they also accumulate immediately below the crypt
epithelium [26]. Therefore, if plasma-cell differentiation
renders a cell competent to replicate EBV, as some results
suggest [27], one can imagine that antigenic re-stimulation
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of an EBV-infected memory cell could on the one hand
direct virus replication to a mucosal site from which infec-
tious virus can be secreted, and on the other serve to
replenish the latently infected memory B-cell pool.
But these speculations skirt around some of the more
immediate issues raised by the observations of Uchida
et al. [8]. A number of central questions remain. What is to
be gained by LMP1 diverting infected cells away from
germinal centres? Is such diversion biologically important
or merely a side effect of the multi-faceted LMP1 pheno-
type? How does the pool of EBV-transformed (LMP1-
expressing) lymphoblasts generated during primary virus
infection give rise to EBV-infected (LMP1-negative)
memory B cells? Is there a physiological signal that the
virus exploits to switch off expression of its transforming
proteins at an appropriate stage of B-cell differentiation? If
so, is the previous experience of viral transformation suffi-
cient to impose a memory phenotype on the surviving
cell, and would such virus-induced delivery into memory
necessarily require somatic hypermutation? However dif-
ficult these questions posed by a virus from the human
B-cell system, it is now a sure bet that murine models can
help to answer them.
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